Eli Lilly, a global healthcare company, agreed to acquire Disarm Therapeutics, a biotechnology company, from private equity firms Atlas Venture, Biogenerator, and Lightstone Ventures, for $135m. "Disarm's innovative approach to treating axonal degeneration holds tremendous promise for addressing a wide spectrum of neurological diseases, and we have made significant strides toward enabling potentially transformative therapies. Lilly is ideally suited to advance this exciting new approach to treating axonal degeneration, and we look forward to seeing patients benefit from the work that Disarm initiated," Alvin Shih, Disarm Chief Executive Officer.